Importantly, the beneficial anti-cancer effects of PDI-1 on T cell abundance, cytokine production, and PD-L1 expression were as good as or superior to the effects of the anti-PD-L1 mAb atezolizumab (Supplementary Figures 7A–C). Here, CD274 is linked to cancer.